Salix Pharmaceuticals picked up FDA approval for an orphan therapy, giving the company another revenue source as it plots a tax-saving move to Ireland.
In its second FDA nod this week, Salix Pharmaceuticals won the go-ahead for Ruconest, its first-in-class treatment for a rare genetic disease, hereditary angioedema.
Yet another U.S. company is orchestrating a deal that will allow it to move overseas and slash its tax rate. Salix Pharmaceuticals of North Carolina says it will merge with an Ireland-based unit of Cosmo Pharmaceutical and buy out some of its patents for drugs to treat gastrointestinal diseases for $2.7 billion in stock.
Should Salix Pharmaceuticals snap up its North Carolina neighbor Furiex Pharmaceuticals? The latter's bowel drug could slide right in to Salix's business, analysts said. And Furiex is scouting around for a potential buyer, Bloomberg reports.
Salix Pharmaceuticals, the gastrointestinal drug specialist, has snapped up fellow specialty drugmaker Santarus in a $2.6 billion all-cash buyout.
EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.
Our readers who regularly check our website know that we kept up with the news online. But for everyone else, here's a roundup of the regulatory actions you may have missed.
On the last day of the year, the FDA gave a thumbs up to the second botanical prescription drug it has ever approved, a full 6 years after the first was sanctioned. The recipient of this rare distinction was Fulyzaq, a drug marketed by Salix Pharmaceuticals for the treatment of diarrhea in HIV/AIDS patients who are on anti-retroviral therapy.
Racking up yet another year-end approval, the FDA today OK'd Salix's crofelemer for use in treating HIV-related diarrhea. The drug, to be marketed as Fulyzaq, is derived from the red sap of the Croton lechleri plant, making this the second botanical drug ever approved by the FDA.
Breaking from a long string of trial failures, AstraZeneca offered up positive data from a pair of late-stage Phase III study of naloxegol, an experimental drug for opioid-induced constipation in-licensed from Nektar ($NKTR) in a $1.5 billion deal. The treatment hit its endpoint for both doses in one study while only the high dose cleared that bar in the second study.